FDA Pediatric Request Procedure Should Be Shortened - R.W. Johnson
This article was originally published in The Tan Sheet
Executive Summary
Inclusion in FDA's "priority list" of pediatric drugs should constitute a pediatric study request for a drug, R.W. Johnson Pharmaceutical Research Institute Pediatric Drug Development Global Head Stephen Spielberg, MD/PhD, suggested at an FDA Modernization Act oversight hearing by the House Commerce Committee Oct. 7.